biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
NovaPharmaNews editorial coverage mentioning Revolution Medicines — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
News & analysis
NovaPharmaNews articles mentioning Revolution Medicines — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Revolution Medicines — regulatory, clinical, and market analysis.
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.
Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
Revolution Medicines’ daraxonrasib nearly doubled median survival in a Phase 3 trial for pancreatic cancer, offering a new standard of care. This article analyzes the clinical data, side effect profile, and competitive implications for pharma teams.
Revolution Medicine Pancreatic Cancer: Demand Surge Strains Daraxonrasib Access
Revolution Medicines' daraxonrasib has shown a dramatic overall survival benefit in pancreatic cancer, but patient demand is overwhelming the expanded access program. For pharma strategists, the supply-demand imbalance signals potential launch revenue upside and commercial execution risk.
ASCO 2026 Preview: Key Data and Trends in Cancer Research
This ASCO preview highlights crucial developments in cancer research, focusing on key data presentations and emerging trends that will shape the oncology landscape. Investors and BD teams should monitor these advancements for strategic insights.